Skip to content
DE

Triphala: the Ayurvedic herbal blend for digestion and what the evidence shows

Clinical review pending

Triphala: research on the Ayurvedic herbal blend, its digestive effects, and open questions about tolerability and product quality.

Does triphala help with constipation? For this Ayurvedic blend of three fruits, the answer so far comes with real limits. The most relevant clinical study tested a preparation that also contained senna and psyllium husk, so the benefit of triphala on its own remains an open question. When comparing products, possible drug interactions and the quality of the particular blend matter too.

What is triphala?

Triphala is made from three dried fruits: amalaki (Phyllanthus emblica), bibhitaki (Terminalia bellerica) and haritaki (Terminalia chebula). The blend is one of the most frequently mentioned formulas in the classical Ayurvedic texts. Traditionally the fruits are ground into a powder known as churna. Today triphala is also sold as tablets, capsules and liquid extracts.

The fruits contain a large number of compounds, and the amounts vary from product to product. The ratio in which the fruits are mixed is not always the same either. That makes it hard to pin any observed effect on a single ingredient. A 2017 review describes traditional uses and clinical data. The 2026 overview deals with the plant compounds and their pharmacology.

What triphala contains

Metabolome analyses of all three fruits catalog a wide range of compounds. They reveal a complex mixture of polyphenols and tannins (the astringent compounds also found in tea and wine). Amalaki is rich in vitamin C, gallic acid, ellagic acid and emblicanins. Bibhitaki provides gallotannins, ellagitannins and lignans. Haritaki contains chebulagic acid, chebulinic acid and other ellagitannins. The tannin and polyphenol content of the genus Terminalia has been studied particularly well.

Measurable antioxidant activity has been described for the fruits. The study of polyphenols and antioxidant properties cited here, however, does not include amalaki. Its results are therefore not enough to establish such properties for all three triphala fruits or for the blend as a whole.

Ellagitannins are not absorbed as intact molecules. Gut microbes convert them into urolithins, which are biologically active in their own right. Researchers are studying both this conversion by the gut microbiota and possible effects of the resulting metabolites on gut health and mitochondria. Whether taking triphala improves health through this route cannot yet be concluded from this work.

Where triphala comes from and what it is often confused with

Triphala’s documented use in Ayurvedic medicine goes back thousands of years. There it belongs to the rasayanas: rejuvenating and strengthening remedies meant to promote longevity and vitality. This traditional classification shapes the use of triphala in classical Ayurvedic therapy.

All three source trees are native to South Asia. Phyllanthus emblica grows in India, Sri Lanka and Southeast Asia; the two Terminalia species have a similar range.

Since the 2000s, the medicinal properties traditionally attributed to triphala have been studied more intensively in the clinic. Reviews trace the path from traditional knowledge to scientific investigation of triphala and amalaki. These include the publication linked here and a further review.

When comparing products, check the ingredient list: a pure amalaki extract, often sold as “amla,” is not triphala. The same goes for generic Ayurvedic “detox” blends, which may contain entirely different plants.

How triphala might work: polyphenols, tannins and the gut

Polyphenols and tannins are at the center of the proposed explanations for triphala’s effects. The candidates under discussion are changes in the gut microbiome, the formation of urolithins from ellagitannins, antioxidant activity and a dose-dependent laxative effect. Whether that last effect can really be traced to the tannin content is still unresolved.

Several components probably contribute to any effects. A single pathway is therefore unlikely to capture the whole blend. Clinical trials have to show whether these mechanisms lead to a noticeable improvement in people.

Proposed mechanisms

One explanation offered for more regular bowel movements is an osmotic effect, meaning water is held in the gut. Together with a mild laxative action, this mechanism is mainly attributed to haritaki and its tannins. How much of a role the tannins actually play, though, has not been adequately established. Nor can usual doses reliably be described as “mild.” Larger amounts can cause unpleasant symptoms, so the dose also affects how well triphala is tolerated.

A recent review covers the interplay between triphala, the gut microbiome and metabolic disorders. Animal studies and small human studies suggest that the makeup of the microbiome could shift in favor of bacteria that produce short-chain fatty acids. These SCFAs supply energy to the cells lining the colon and support the gut barrier.

Vitamin C from amalaki and the blend’s polyphenols are also linked to measurable free-radical scavenging. The analytical study cited for this, however, does not cover all three triphala fruits. And antioxidant activity in the lab says nothing on its own about a clinical benefit of the blend.

Another line of research concerns the conversion of ellagitannins into urolithins by gut microbes. Independently of triphala, urolithins have been studied for anti-inflammatory effects and for their influence on mitophagy, the targeted breakdown of damaged mitochondria. Research on these bioactive ellagitannin metabolites helps clarify possible mechanisms. Its findings cannot simply be carried over to taking triphala, though.

In Ayurveda, triphala is considered a remedy that balances all three doshas and is used as a versatile tonic. This traditional concept translates only partly into Western pharmacology.

Pharmacokinetics: why the same milligram figure does not mean the same active dose

How the body absorbs, transforms and eliminates triphala has so far been described only sketchily. Together these processes are called pharmacokinetics, and they differ for each component.

Gallic acid and ellagic acid are absorbed to different extents, and the makeup of the gut microbiome is one of the factors involved. Most ellagitannins do not enter the body unchanged: in the gut they are first broken down into ellagic acid, which resident bacteria then convert into urolithins.

Vitamin C from amalaki follows the usual absorption and excretion routes of ascorbate. It is absorbed in the small intestine and excreted through the kidneys, and at higher doses absorption becomes saturated. Chebulagic acid and chebulinic acid from haritaki have their own, less well studied profiles.

Two packages with the same milligram figure can therefore deliver very different amounts of active components. The differences in the composition of the three fruits contribute to this. Standardization markers listed on a certificate of analysis (COA) can make comparison easier. What matters is which compounds were measured, which batch the certificate refers to and who carried out the analysis. Independent testing is an additional quality factor.

What the studies show

Triphala has been studied for a range of health uses, and the strength of the evidence varies widely. The clearest signals concern bowel regularity and oral health. Results for metabolic markers are mixed, and claims of anticancer effects rest entirely on preclinical research.

The following categories are used here for orientation. How they are assigned to the individual uses is provisional and is not an independently reviewed evidence rating:

  • Strong: At least 2 well-designed randomized controlled trials (RCTs) in humans with a clinically relevant endpoint, ideally backed by a meta-analysis showing a consistent direction of effect.
  • Moderate: At least 1 human RCT with a clinically relevant endpoint, or several smaller RCTs with mixed results.
  • Limited: Only small studies with fewer than 50 participants, short studies lasting less than 8 weeks or methodologically weak human studies; alternatively, only observational data in humans.
  • Animal / preclinical only: No completed efficacy studies in humans; only in vitro work, animal models or phase I safety data.
  • Anecdotal: No controlled evidence. This includes case reports, testimonials, mechanistic plausibility or marketing claims not backed by published data.

Bowel regularity and constipation relief: limited to moderate evidence

In an open-label clinical study in functional constipation, stool frequency and consistency improved with a triphala-containing formula. The preparation, however, also contained senna and psyllium husk. How much of the result was due to triphala therefore cannot be determined.

The study had further limitations: the sample was small, there was no placebo control and treatment was not blinded. The laxative effect described is also considered dose-dependent, and whether it comes from the tannins remains unclear. Too large a dose can lead to loose stools.

The AGA-ACG clinical guideline on chronic idiopathic constipation does not include triphala. No recommendation for triphala is reported for the 2025 British Dietetic Association guideline on the dietary management of chronic constipation either. Triphala might help some people have more regular bowel movements, but it is not among the established recommendations of gastroenterology guidelines.

Oral health: plaque and gum inflammation, with limited to moderate evidence

There are several controlled studies on oral health. They offer concrete indications of a possible effect of triphala mouthwashes on plaque and gum inflammation, but they do not yet support a broad recommendation for use.

One RCT in schoolchildren compared a 0.4% triphala mouthwash with a 0.12% chlorhexidine mouthwash. Comparable results for plaque and gum inflammation are reported; this study link is given for it. Similar plaque-control results are described from an earlier crossover RCT, in which participants used both mouthwashes one after the other. This study link is given for that one.

A systematic review and meta-analysis of Ayurvedic and herbal plaque-control agents in gingivitis summarizes the evidence. Chlorhexidine remains the clinical standard. Most studies are small and were done in schoolchildren, so their results apply to adults only to a limited extent.

Metabolic and blood lipid markers: limited evidence

A systematic review of triphala looked at blood lipids, glucose and anthropometric measures (body measurements). Across the studies, effects were small and inconsistent. Results for LDL cholesterol, triglycerides and fasting glucose did not consistently agree, and different formulas may have contributed to this. This publication is given as the source.

The cardiovascular pharmacology of Emblica officinalis has been studied separately. That work found some indications of lipid-lowering effects specifically for amalaki. This publication is linked for it.

In some populations triphala might slightly improve individual metabolic markers. The data do not, however, justify using it in place of established cardiometabolic treatment.

Anticancer effects: animal / preclinical only

For the claim that triphala can prevent or treat cancer, the data summarized here include no human RCT. Advertising promises along these lines go well beyond this evidence.

Preclinical work has examined, for example, synergistic effects of P. emblica and T. bellerica with cytotoxic drugs. Such findings can point to biological mechanisms. But reviews of molecular mechanisms also remain in preclinical territory. They are no basis for clinical treatment decisions.

Nor can the studies described here support a treatment effect in irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) or other diagnosed digestive disorders. These conditions need a medical evaluation. For “detoxifying” the liver or other organs, controlled evidence is lacking here. That leaves the question of an effect open; it does not prove that triphala does nothing at all.

No therapeutic indication approved by the US FDA is reported for triphala. Nor does it replace medically indicated treatment of constipation. The current gastroenterology guidelines on chronic idiopathic constipation do not include it.

Forms, standardization and quality markers

Triphala is available as a powder (churna), tablet, capsule and liquid extract. With a blend of several plants, the milligram figure is often not enough for comparison. The mixing ratio, extraction method and raw-material quality all affect how much of each active component a product contains. Standardization is inconsistent.

The traditional powder contains the polyphenols and tannins of the processed fruits and tastes correspondingly bitter. The tannin content contributes to that taste, and a large share of the presumed effects is also attributed to it. Tablets and capsules are the most common modern forms and make triphala easier to take. How well they are standardized, however, varies considerably. Information on the mixing ratio and on markers such as tannin or ellagic acid content, on the label or in the COA, helps with comparison.

Liquid extracts contain the formula in concentrated form, although concentrations can differ considerably. Without independent verification, label claims are not always reliable. A phase I safety study of orally taken aqueous triphala extract in healthy volunteers found no serious adverse events at the doses tested. That offers limited evidence on the tolerability of this specific extract under study conditions.

One documented quality risk of Ayurvedic supplements is contamination with lead, mercury and arsenic. Independent testing, for instance by USP, NSF International or ConsumerLab, is therefore relevant before use. A COA issued only by the manufacturer does not provide that independent check. The declared mixing ratio and the standardization markers in the COA also help place a product.

Regulatory status

For the US, the following classification is described as of May 2026: triphala is regulated as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) and has no FDA approval to treat any disease. The FDA does not review dietary supplements for efficacy before they go on the market. This regulatory information has not been independently verified and cannot be applied to Germany or the EU.

The FDA has warned about heavy-metal contamination in some Ayurvedic supplements. Lead, mercury and arsenic were found in products sold in the US. Amalaki, bibhitaki and haritaki each have their own regulatory history. There appears to be no separate New Dietary Ingredient (NDI) notification to the FDA for the combined triphala formula; this remains unconfirmed.

When choosing a product, what counts is credible independent testing for identity and contaminants, especially lead, mercury and arsenic. Only products tested this way should be considered for use. A manufacturer’s COA carries less weight than independent third-party testing.

Safety profile

At the doses tested in each case, the studies described paint a relatively unremarkable picture. That is not yet enough for a comprehensive safety assessment. The most common effect is soft to loose stools, depending on the dose. A laxative effect is discussed as the explanation; the exact contribution of the tannins is unclear.

Possible drug interactions deserve particular attention, especially with anticoagulants and with drugs that have a narrow therapeutic index. For the latter, the effective dose lies close to a dose that can cause harm.

Reported side effects

The most frequently documented effects were loose stools and abdominal discomfort. Both depend on the dose and usually subside once the dose is reduced. Mild headaches occurred occasionally. A phase I safety study of oral aqueous triphala extract in healthy volunteers found no serious adverse events at the doses tested.

Long-term safety remains open, since large studies over longer periods are lacking. On top of that there is a separate risk from heavy metals in poorly manufactured Ayurvedic products, regardless of how the herbal blend itself acts in the body.

Drug interactions

Possible interactions differ by drug and by the presumed mechanism. The severity ratings below are provisional and have not been independently reviewed. Each medication needs its own assessment.

  • For anticoagulants such as warfarin and direct oral anticoagulants (DOACs), the rating is “moderate.” A theoretically increased bleeding risk is discussed for haritaki, based on the tannin profile of Terminalia and preclinical work on inhibition of platelet function. Taking them together requires coordination with a doctor.
  • For CYP3A4 substrates, the rating is “moderate, theoretical.” Triphala showed potential in vitro to inhibit CYP enzymes involved in breaking down drugs. This matters especially for drugs with a narrow therapeutic index that are metabolized by these enzymes.
  • For diabetes medications, the rating is “minor, additive.” A 2021 systematic review is cited as pointing to a small blood-sugar-lowering effect. With insulin or sulfonylureas, a possible added effect argues for appropriate monitoring.
  • For other oral medications, the rating is “minor, depends on timing.” Tannins could bind drugs and reduce their absorption. Where an interaction is documented, spacing doses 1–2 hours apart is mentioned as a possible precaution. Whether this gap makes sense and is long enough has to be checked for each specific drug. It does not automatically prevent enzyme inhibition.

There are far fewer data on interactions of multi-herb preparations than on single active ingredients. If you take warfarin, DOACs or drugs with a narrow therapeutic index, it is therefore especially important to coordinate with a doctor before starting triphala.

Pregnancy, breastfeeding and special populations

Triphala is generally avoided during pregnancy. The traditional caution rests on possible effects of haritaki that may promote contractions or stimulate the uterine muscle. According to the data described here, there are no controlled human data that could dispel these concerns.

There are no controlled data for breastfeeding either, so avoiding use is the cautious approach. For people with impaired liver or kidney function, no specific problems with individual ingredients are documented here. The data are so thin, however, that medical advice is appropriate.

In children, oral health studies provide some safety information on local use in the mouth, including a 2021 RCT of a triphala mouthwash in schoolchildren. Doses for systemic use, where compounds act in the body after being swallowed, are not adequately described, however. Current evidence does not support applying adult intake data to children.

Who should avoid triphala

Pregnant and breastfeeding women, people with active gastrointestinal disease and people taking certain medications should avoid triphala or use it only after talking to a doctor. The same applies to children outside the studied use as a mouthwash in schoolchildren. The reasons differ: some warnings rest on theoretical risks, others on missing safety data.

  • In pregnancy and breastfeeding, controlled human data are lacking. Traditional caution concerns, among other things, possible uterus-stimulating effects of haritaki.
  • Active gastrointestinal conditions such as IBD, severe irritable bowel syndrome or chronic diarrhea need a gastroenterology workup. Self-treatment with herbal blends is not a suitable substitute.
  • With warfarin, DOACs or drugs with a narrow therapeutic index, triphala should only be used after coordinating with a doctor.
  • For persistent constipation, a duration of more than 2–4 weeks is given as a reason to see a primary care doctor. This time frame is not established as a general rule: the cited publication on the management of constipation refers to older adults. Taking triphala for longer does not replace a medical evaluation.
  • In children, doses for systemic use are not adequately described. The mouthwash studies in schoolchildren do not answer this question.

In these situations, a doctor who knows the full medication list and relevant lab values should be involved in the decision before starting.

Inflammation, metabolism and gut health can partly be captured through lab values. That raises the question of whether such values could make possible changes visible while someone takes triphala. Measurements before starting and after 8–12 weeks are suggested as checkpoints to complement subjective impressions. A specific guideline basis for such a routine testing program is lacking, however.

The markers mentioned are not validated tests of a triphala effect. A before-and-after comparison on its own does not prove a causal treatment effect either. Whether testing makes sense depends on symptoms, existing conditions and the clinical question. The suggestions below are therefore not a general recommendation for lab tests before taking triphala.

  • hs-CRP is a marker of systemic inflammation. The underlying hypothesis is that possible antioxidant and anti-inflammatory effects of the polyphenols and of the urolithins formed from ellagitannins could show up in it, provided they are clinically effective. A repeat measurement after 8–12 weeks could provide an objective trend value, but it would not prove a triphala effect.
  • A lipid panel here includes ApoB, LDL cholesterol, HDL cholesterol and triglycerides. A 2021 systematic review reported small effects on blood lipids in some studies. The suggestion to capture possible changes with a baseline measurement and a repeat after 8–12 weeks builds on this observation.
  • For fasting glucose, a small blood-sugar-lowering signal from the 2021 paper is described. The suggestion is fasting glucose and HbA1c after 12 weeks, to capture both the current value and the average blood sugar over the past roughly 3 months.
  • Fecal calprotectin can point to gut inflammation when symptoms suggest inflammatory bowel disease. Such symptoms should be evaluated before any self-treatment. A raised value is a reason for clinical evaluation, not a signal to use triphala.

This suggestion puts particular weight on baseline values for hs-CRP and blood lipids, which can help put later changes in context. One difficulty remains: values that were previously out of line can drift back toward the average on their own, a phenomenon called regression to the mean. Placebo effects can also shape perceived improvement. Without a baseline measurement these explanations are harder to tell apart, and even with baseline values they cannot be ruled out. With triphala this is especially relevant, given inconsistent extracts and the small effects observed.

When triphala is the wrong place to start

Persistent constipation, unexplained upper abdominal discomfort (dyspepsia), unintended weight loss or blood in the stool should be checked by a doctor. For constipation a duration of more than 2–4 weeks is given, but this exact time frame is not established as a generally applicable threshold. Self-treatment with triphala does not replace an examination for these symptoms.

Professional guidance comes from the AGA-ACG guideline on the pharmacological management of chronic idiopathic constipation and the 2025 BDA guideline on the dietary management of chronic constipation. Gastrointestinal warning signs need assessment by a doctor, and by a gastroenterologist where appropriate. A prolonged trial of a supplement is not an adequate substitute.

With inconsistently composed multi-herb preparations and small observed effects in particular, a clearly documented starting point helps. Which symptoms, findings or measurements are relevant depends on the individual clinical situation.

Frequently asked questions

What is triphala powder?

Triphala powder is a traditional Ayurvedic blend of three fruits: amalaki (Phyllanthus emblica, also called Indian gooseberry), bibhitaki (Terminalia bellerica) and haritaki (Terminalia chebula). The formula has been used for centuries for general well-being and to support digestion. Today it is marketed mainly as a digestive aid.

Does triphala actually help with digestion?

There is only limited evidence for more regular bowel movements and relief of constipation. The most relevant study tested an herbal formula that also contained senna and psyllium husk. How much of the effect came from triphala cannot be inferred from it.

In some people triphala might make bowel movements slightly more regular. That assessment, however, rests on limited data from open-label studies. The AGA-ACG and BDA constipation guidelines mentioned here do not include triphala.

For oral health there is some evidence from one randomized controlled trial. Claims of anticancer effects, by contrast, rest entirely on preclinical data; evidence in humans is lacking.

What triphala doses have been used in studies?

Studies tested 500 mg to 3 g of standardized triphala powder or extract per day, usually over 4–12 weeks and in a range of populations. The extracts were not uniformly standardized, which makes comparison harder. These amounts describe study conditions and are not an individually reviewed intake recommendation.

What are the side effects of triphala?

The most frequently reported effects at higher doses were loose stools and mild gastrointestinal discomfort. A dose-dependent laxative effect is discussed as the explanation. Whether the tannins are responsible is still unresolved.

A phase I safety study of aqueous triphala extract found no serious adverse effects at the doses tested. Long-term safety has not been fully established by this.

Is triphala FDA-approved?

No FDA approval for a therapeutic indication is reported for triphala. According to the information given here, which has not been independently verified and reflects the situation as of May 2026, it is sold in the US as a dietary supplement under DSHEA. This does not describe its regulatory status in Germany or the EU.

For Ayurvedic multi-herb products, independent testing for heavy metals is relevant, because such contamination has been documented.

How does triphala compare with senna or psyllium husk for constipation?

Senna is a stimulant laxative that directly prompts the bowel to move. Psyllium husk is a bulk-forming fiber that clinical guidelines on constipation frequently include.

For triphala as a multi-herb formula, clinical data are limited. Proposed mechanisms include a laxative effect attributed to tannins and effects of polyphenols on signaling pathways in the gut. These presumed mechanisms are not enough to establish comparable effectiveness.

Who should avoid triphala?

Pregnant women should generally avoid triphala. The traditional caution rests on possible uterus-stimulating effects of haritaki, and controlled human safety data in pregnancy are lacking.

Anyone taking anticoagulants needs to talk to a doctor first. A theoretical bleeding risk is inferred for haritaki from the tannin profile of Terminalia. Triphala could also affect CYP enzymes that metabolize certain medications. This is especially relevant for drugs with a narrow therapeutic index.

Which blood tests make sense before taking triphala?

A general recommendation for a routine lab program before triphala cannot be derived from the available information. The following suggested tests lack a specific guideline basis:

  • hs-CRP, meaning high-sensitivity C-reactive protein.
  • A lipid panel.
  • Fasting glucose.
  • Fecal calprotectin, if symptoms could point to inflammatory bowel disease.

The idea behind them is to capture possible anti-inflammatory and metabolic effects. The values do not, however, prove a triphala effect.

Calprotectin is also a stool test, not a blood test. With relevant gastrointestinal symptoms, the value can point to inflammation and so to a need for medical evaluation. Whether testing is needed depends on the symptoms and the medical question.

Sources

  • Peterson CT, Denniston K, Chopra D (2017). Therapeutic Uses of Triphala in Ayurvedic Medicine. Journal of alternative and complementary medicine (New York, N.Y.), 23(8), 607-614. https://doi.org/10.1089/acm.2017.0083
  • Thallada V, Monika N, Dinesh T, Kusuma G, Ghosh K, Chitra S (2026). The Multifaceted Benefits of Triphala: Uncovering Phytochemical and Pharmacological Properties From Antiquity to Modern Times. Chemistry & biodiversity, 23(1), e01825. https://doi.org/10.1002/cbdv.202501825
  • Hegde SN, K LD, Choudhary M, Menon N, Singh G (2024). A comprehensive metabolome profiling of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica to explore the medicinal potential of Triphala. Scientific reports, 14(1), 31635. https://doi.org/10.1038/s41598-024-80544-6
  • Cock IE (2015). The medicinal properties and phytochemistry of plants of the genus Terminalia (Combretaceae). Inflammopharmacology, 23(5), 203-29. https://doi.org/10.1007/s10787-015-0246-z
  • Pfundstein B, El Desouky SK, Hull WE, Haubner R, Erben G, Owen RW (2010). Polyphenolic compounds in the fruits of Egyptian medicinal plants (Terminalia bellerica, Terminalia chebula and Terminalia horrida): characterization, quantitation and determination of antioxidant capacities. Phytochemistry, 71(10), 1132-48. https://doi.org/10.1016/j.phytochem.2010.03.018
  • Ribeiro M, Alvarenga L, Cardozo LFMF, Baptista BG, Nascimento D, Esgalhado M, Mafra D (2025). Urolithin as a Metabolite of Ellagitannins and Ellagic Acid from Fruits and Nuts Produced by the Gut Microbiota: Its Role on Non-Communicable Diseases. Current nutrition reports, 14(1), 55. https://doi.org/10.1007/s13668-025-00645-0
  • Tomás-Barberán FA, González-Sarrías A, García-Villalba R, Núñez-Sánchez MA, Selma MV, García-Conesa MT, Espín JC (2017). Urolithins, the rescue of ‘old’ metabolites to understand a ‘new’ concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Molecular nutrition & food research, 61(1). https://doi.org/10.1002/mnfr.201500901
  • Ahmed S, Ding X, Sharma A (2021). Exploring scientific validation of Triphala Rasayana in ayurveda as a source of rejuvenation for contemporary healthcare: An update. Journal of ethnopharmacology, 273, 113829. https://doi.org/10.1016/j.jep.2021.113829
  • Baliga MS, Meera S, Mathai B, Rai MP, Pawar V, Palatty PL (2012). Scientific validation of the ethnomedicinal properties of the Ayurvedic drug Triphala: a review. Chinese journal of integrative medicine, 18(12), 946-54. https://doi.org/10.1007/s11655-012-1299-x
  • Yadav SS, Singh MK, Singh PK, Kumar V (2017). Traditional knowledge to clinical trials: A review on therapeutic actions of Emblica officinalis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 93, 1292-1302. https://doi.org/10.1016/j.biopha.2017.07.065
  • Gurjar S, Taliyan R, Kumari S, Kesharwani P (2025). The interplay of triphala and its constituents with respect to metabolic disorders and gut-microbiome. Fitoterapia, 184, 106642. https://doi.org/10.1016/j.fitote.2025.106642
  • Munshi R, Bhalerao S, Rathi P, Kuber VV, Nipanikar SU, Kadbhane KP (2011). An open-label, prospective clinical study to evaluate the efficacy and safety of TLPL/AY/01/2008 in the management of functional constipation. Journal of Ayurveda and integrative medicine, 2(3), 144-52. https://doi.org/10.4103/0975-9476.85554
  • Chang L, Chey WD, Imdad A, Almario CV, Bharucha AE, Diem S, Greer KB, Hanson B, Harris LA, Ko C, Murad MH, Patel A, Shah ED, Lembo AJ, Sultan S (2023). American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology, 164(7), 1086-1106. https://doi.org/10.1053/j.gastro.2023.03.214
  • Dimidi E, van der Schoot A, Barrett K, Farmer AD, Lomer MC, Scott SM, Whelan K (2025). British Dietetic Association Guidelines for the Dietary Management of Chronic Constipation in Adults. Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 38(5), e70133. https://doi.org/10.1111/jhn.70133
  • Bhor K, Shetty V, Garcha V, Ambildhok K, Vinay V, Nimbulkar G (2021). Effect of 0.4% Triphala and 0.12% chlorhexidine mouthwash on dental plaque, gingival inflammation, and microbial growth in 14-15-year-old schoolchildren: A randomized controlled clinical trial. Journal of Indian Society of Periodontology, 25(6), 518-524. https://doi.org/10.4103/jisp.jisp_338_20
  • Chainani SH, Siddana S, Reddy C, Manjunathappa TH, Manjunath M, Rudraswamy S (2014). Antiplaque and antigingivitis efficacy of triphala and chlorhexidine mouthrinse among schoolchildren - a cross-over, double-blind, randomised controlled trial. Oral health & preventive dentistry, 12(3), 209-17. https://doi.org/10.3290/j.ohpd.a32674
  • Javed D, Dixit AK, Anwar S, Rai A, Krishan K (2023). Ayurvedic and herbal plaque control agents in gingivitis: A systematic review and meta-analysis of randomized controlled trials. Journal of education and health promotion, 12, 378. https://doi.org/10.4103/jehp.jehp_204_23
  • Phimarn W, Sungthong B, Itabe H (2021). Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review. Journal of evidence-based integrative medicine, 26, 2515690X211011038. https://doi.org/10.1177/2515690X211011038
  • Hashem-Dabaghian F, Ziaee M, Ghaffari S, Nabati F, Kianbakht S (2018). A systematic review on the cardiovascular pharmacology of Emblica officinalis Gaertn. Journal of cardiovascular and thoracic research, 10(3), 118-128. https://doi.org/10.15171/jcvtr.2018.20
  • Pinmai K, Chunlaratthanabhorn S, Ngamkitidechakul C, Soonthornchareon N, Hahnvajanawong C (2008). Synergistic growth inhibitory effects of Phyllanthus emblica and Terminalia bellerica extracts with conventional cytotoxic agents: doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells. World journal of gastroenterology, 14(10), 1491-7. https://doi.org/10.3748/wjg.14.1491
  • Kumar G, Madka V, Pathuri G, Ganta V, Rao CV (2022). Molecular Mechanisms of Cancer Prevention by Gooseberry (. Nutrition and cancer, 74(7), 2291-2302. https://doi.org/10.1080/01635581.2021.2008988
  • Phetkate P, Kummalue T, Rinthong PO, Kietinun S, Sriyakul K (2020). Study of the safety of oral Triphala aqueous extract on healthy volunteers. Journal of integrative medicine, 18(1), 35-40. https://doi.org/10.1016/j.joim.2019.10.002
  • Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, Thuppil V, Kales SN (2008). Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA, 300(8), 915-23. https://doi.org/10.1001/jama.300.8.915
  • Ponnusankar S, Pandit S, Babu R, Bandyopadhyay A, Mukherjee PK (2011). Cytochrome P450 inhibitory potential of Triphala–a Rasayana from Ayurveda. Journal of ethnopharmacology, 133(1), 120-5. https://doi.org/10.1016/j.jep.2010.09.022
  • Mounsey A, Raleigh M, Wilson A (2015). Management of Constipation in Older Adults. American family physician, 92(6), 500-4. https://pubmed.ncbi.nlm.nih.gov/26371734/